US20030180290A1
(en)
*
|
1995-06-07 |
2003-09-25 |
Idec Pharmaceuticals Corporation |
Anti-CD80 antibody having ADCC activity for ADCC mediated killing of B cell lymphoma cells alone or in combination with other therapies
|
US7696325B2
(en)
|
1999-03-10 |
2010-04-13 |
Chugai Seiyaku Kabushiki Kaisha |
Polypeptide inducing apoptosis
|
KR20080039550A
(ko)
*
|
1999-05-07 |
2008-05-07 |
제넨테크, 인크. |
B 세포 표면 마커에 결합하는 길항물질을 이용한 자가면역질환의 치료
|
IL147547A0
(en)
*
|
1999-07-12 |
2002-08-14 |
Genentech Inc |
Blocking immune response to a foreign antigen using an antagonist which binds to cd20
|
US20020028178A1
(en)
*
|
2000-07-12 |
2002-03-07 |
Nabil Hanna |
Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
|
ATE511857T1
(de)
*
|
2000-02-16 |
2011-06-15 |
Genentech Inc |
Anti-april monoklonaler antikörper und deren verwendung zur behandlung von immunerkrankungen oder krebs
|
AU8729101A
(en)
*
|
2000-03-31 |
2001-10-15 |
Idec Pharma Corp |
Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for the treatment of B cell lymphoma
|
CN1592645A
(zh)
*
|
2000-09-18 |
2005-03-09 |
拜奥根Idec公司 |
使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法
|
ATE391174T1
(de)
|
2000-10-20 |
2008-04-15 |
Chugai Pharmaceutical Co Ltd |
Modifizierter tpo-agonisten antikörper
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20070065436A1
(en)
*
|
2001-01-31 |
2007-03-22 |
Biogen Idec Inc. |
Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
|
US20030211107A1
(en)
*
|
2002-01-31 |
2003-11-13 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
US20020159996A1
(en)
*
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
CN100574803C
(zh)
*
|
2001-01-31 |
2009-12-30 |
拜奥根Idec公司 |
免疫调节抗体在***性疾病中的用途
|
US20030103971A1
(en)
*
|
2001-11-09 |
2003-06-05 |
Kandasamy Hariharan |
Immunoregulatory antibodies and uses thereof
|
EP1408950B1
(en)
*
|
2001-07-11 |
2007-04-25 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Methods of treating cytokine mediated diseases
|
BR0211614A
(pt)
*
|
2001-08-03 |
2006-10-31 |
Genentech Inc |
polipeptìdeo tacis e br3 e empregos dos mesmos
|
US20110045005A1
(en)
|
2001-10-19 |
2011-02-24 |
Craig Crowley |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
WO2003039486A2
(en)
*
|
2001-11-09 |
2003-05-15 |
Idec Pharmaceuticals Corporation |
Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
|
TW200303759A
(en)
*
|
2001-11-27 |
2003-09-16 |
Schering Corp |
Methods for treating cancer
|
US8287864B2
(en)
*
|
2002-02-14 |
2012-10-16 |
Immunomedics, Inc. |
Structural variants of antibodies for improved therapeutic characteristics
|
US20160279239A1
(en)
|
2011-05-02 |
2016-09-29 |
Immunomedics, Inc. |
Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
|
CN102174108B
(zh)
*
|
2002-03-01 |
2016-06-29 |
免疫医疗公司 |
内在化抗-cd74抗体和使用方法
|
US20070207142A1
(en)
*
|
2002-05-08 |
2007-09-06 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
US20030219818A1
(en)
*
|
2002-05-10 |
2003-11-27 |
Bohen Sean P. |
Methods and compositions for determining neoplastic disease responsiveness to antibody therapy
|
CN1692127A
(zh)
*
|
2002-07-25 |
2005-11-02 |
健泰科生物技术公司 |
Taci抗体及其用途
|
CN101928344B
(zh)
|
2002-10-17 |
2014-08-13 |
根马布股份公司 |
抗cd20的人单克隆抗体
|
AU2003291549A1
(en)
*
|
2002-11-15 |
2004-06-15 |
Morehouse School Of Medicine |
Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
|
HU227217B1
(en)
*
|
2002-12-16 |
2010-11-29 |
Genentech Inc |
Immunoglobulin variants and uses thereof
|
EP1444989A1
(en)
*
|
2003-02-07 |
2004-08-11 |
Giorgio Dr. Stassi |
Sensitizing cells for apoptosis by selectively blocking cytokines
|
JP2004279086A
(ja)
|
2003-03-13 |
2004-10-07 |
Konica Minolta Holdings Inc |
放射線画像変換パネル及び放射線画像変換パネルの製造方法
|
JPWO2004087763A1
(ja)
*
|
2003-03-31 |
2006-07-27 |
中外製薬株式会社 |
Cd22に対する改変抗体およびその利用
|
MXPA05010778A
(es)
|
2003-04-09 |
2005-12-12 |
Genentech Inc |
Terapia para enfermedad autoinmune en un paciente con una respuesta inadecuada a un inhibidor tnf-alfa.
|
US20110042260A1
(en)
*
|
2003-04-10 |
2011-02-24 |
Craig Crowley |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
US9416187B2
(en)
|
2003-05-09 |
2016-08-16 |
Duke University |
CD-20 specific antibodies and methods of employing same
|
KR20060027801A
(ko)
|
2003-06-05 |
2006-03-28 |
제넨테크, 인크. |
B 세포 장애에 대한 조합 요법
|
US20050163775A1
(en)
*
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
US20050032130A1
(en)
*
|
2003-07-29 |
2005-02-10 |
Genentech, Inc. |
Neutralizing antibody assay and uses therefor
|
KR20060132554A
(ko)
*
|
2003-08-29 |
2006-12-21 |
제넨테크, 인크. |
안과 질병의 항-cd20 치료
|
EP1689435A4
(en)
*
|
2003-10-22 |
2007-10-03 |
Univ Rochester |
ANTI-THYMOCYTE ANTISERUM AND ITS USE FOR TRIGGERING B-CELL APOPTOSIS
|
RS54450B1
(en)
|
2003-11-05 |
2016-06-30 |
Roche Glycart Ag |
ANTIGEN-BINDING MOLECULES WITH INCREASED BINDING AFFINITY FOR FC RECEPTOR AND EFFECTOR FUNCTION
|
US20050112130A1
(en)
*
|
2003-11-05 |
2005-05-26 |
Bhat Neelima M. |
Enhanced B cell cytotoxicity of CDIM binding antibody
|
SI2295073T1
(sl)
*
|
2003-11-17 |
2014-07-31 |
Genentech, Inc. |
Protitelo proti CD22 za zdravljenje tumorja hematopoetskega izvora
|
MXPA06006864A
(es)
*
|
2003-12-19 |
2006-08-23 |
Genentech Inc |
Deteccion de cd20 en la terapia de enfermedades autoinmunes.
|
US20050191297A1
(en)
*
|
2003-12-19 |
2005-09-01 |
Genentech, Inc. |
Detection of CD20 in transplant rejection
|
US20050136055A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
AU2012200431B2
(en)
*
|
2004-04-09 |
2013-06-27 |
Fondazione Irccs Istituto Nazionale Dei Tumori |
Gene expression markers for predicting response to chemotherapy
|
JP2007532681A
(ja)
*
|
2004-04-16 |
2007-11-15 |
ジェネンテック・インコーポレーテッド |
B細胞の枯渇を増大させる方法
|
JP5848861B2
(ja)
*
|
2004-04-20 |
2016-01-27 |
ジェンマブ エー/エスGenmab A/S |
Cd20に対するヒトモノクローナル抗体
|
EP1773393A2
(en)
*
|
2004-05-05 |
2007-04-18 |
Genentech, Inc. |
Preventing autoimmune disease by using an anti-cd20 antibody
|
PA8635501A1
(es)
*
|
2004-06-04 |
2006-06-02 |
Genentech Inc |
Uso de un anticuerpo para el tratamiento del lupus
|
MY194883A
(en)
*
|
2004-06-04 |
2022-12-21 |
Genentech Inc |
Method for treating multiple sclerosis
|
EP1765399A1
(en)
*
|
2004-07-09 |
2007-03-28 |
Schering Aktiengesellschaft |
Combination therapy with radiolabeled anti-cd20 antibody in the treatment of b-cell lymphoma
|
EP1781818B1
(en)
*
|
2004-07-22 |
2017-09-06 |
Early Detection, LLC |
CANCER AND INFLAMMATION DIAGNOSIS USING ANTI sTNFR ANTIBODIES
|
EP1781378A2
(en)
*
|
2004-07-22 |
2007-05-09 |
Genentech, Inc. |
Method of treating sjögren's syndrome
|
ES2426816T3
(es)
|
2004-08-04 |
2013-10-25 |
Mentrik Biotech, Llc |
Regiones Fc variantes
|
US20060104945A1
(en)
*
|
2004-10-05 |
2006-05-18 |
Choi Yong S |
Enhancement of B cell proliferation by IL-15
|
BRPI0516297A
(pt)
*
|
2004-10-05 |
2008-09-02 |
Genentech Inc |
métodos de tratamento de vasculite e artigos de fabricação
|
US20060188495A1
(en)
*
|
2005-01-13 |
2006-08-24 |
Genentech, Inc. |
Treatment method
|
DOP2006000029A
(es)
*
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
TW200714289A
(en)
*
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
US20160355591A1
(en)
|
2011-05-02 |
2016-12-08 |
Immunomedics, Inc. |
Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
|
EP3050963B1
(en)
|
2005-03-31 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
WO2006106903A1
(ja)
|
2005-03-31 |
2006-10-12 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2構造異性体
|
AR053579A1
(es)
*
|
2005-04-15 |
2007-05-09 |
Genentech Inc |
Tratamiento de la enfermedad inflamatoria intestinal (eii)
|
WO2006114115A1
(de)
*
|
2005-04-26 |
2006-11-02 |
Trion Pharma Gmbh |
Kombination von antikörpern mit glukokortikoiden zur behandlung von krebs
|
CN1865275B
(zh)
*
|
2005-05-17 |
2011-06-15 |
长春华普生物技术有限公司 |
对人b细胞肿瘤有治疗作用的人工合成的单链脱氧核苷酸
|
ATE460672T1
(de)
*
|
2005-05-20 |
2010-03-15 |
Genentech Inc |
Vorbehandlung einer biologischen probe aus einem individuum mit autoimmunkrankheit
|
FR2886298A1
(fr)
*
|
2005-05-24 |
2006-12-01 |
Ifremer |
Anticorps ou fragment d'anticorps couple a un agent immunogene
|
AU2006256041B2
(en)
|
2005-06-10 |
2012-03-29 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
US9241994B2
(en)
|
2005-06-10 |
2016-01-26 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical compositions containing sc(Fv)2
|
NZ565173A
(en)
|
2005-07-25 |
2012-01-12 |
Emergent Product Dev Seattle |
Single dose use of CD20 scFv for rheumatoid arthritis
|
EP2298815B1
(en)
*
|
2005-07-25 |
2015-03-11 |
Emergent Product Development Seattle, LLC |
B-cell reduction using CD37-specific and CD20-specific binding molecules
|
WO2007037795A2
(en)
*
|
2005-08-05 |
2007-04-05 |
Amgen Inc. |
Stable aqueous protein or antibody pharmaceutical formulations and their preparation
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
US20070172847A1
(en)
*
|
2005-11-15 |
2007-07-26 |
The Regents Of The University Of California |
Molecular signaling pathways triggered by rituximab: prognostic, diagnostic, and therapeutic uses
|
AU2006318539B2
(en)
*
|
2005-11-23 |
2012-09-13 |
Genentech, Inc. |
Methods and compositions related to B cell assays
|
WO2007064911A1
(en)
*
|
2005-12-02 |
2007-06-07 |
Biogen Idec Inc. |
Anti-mouse cd20 antibodies and uses thereof
|
DK2009101T3
(en)
|
2006-03-31 |
2018-01-15 |
Chugai Pharmaceutical Co Ltd |
Antibody modification method for purification of a bispecific antibody
|
KR101328756B1
(ko)
|
2006-05-30 |
2013-11-18 |
제넨테크, 인크. |
항체 및 면역접합체 및 이들의 용도
|
WO2007146968A2
(en)
*
|
2006-06-12 |
2007-12-21 |
Trubion Pharmaceuticals, Inc. |
Single-chain multivalent binding proteins with effector function
|
ATE520032T1
(de)
*
|
2006-06-21 |
2011-08-15 |
Apogenix Gmbh |
Differentielle cytokinexpression bei einer menschlichen krebserkrankung
|
US20100086515A1
(en)
*
|
2006-07-06 |
2010-04-08 |
Apogenix Gmbh |
Human il-4 muteins in cancer therapy
|
WO2008007648A1
(fr)
*
|
2006-07-10 |
2008-01-17 |
Institute For Antibodies Co., Ltd. |
Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
|
JP5401314B2
(ja)
*
|
2006-09-08 |
2014-01-29 |
メディミューン,エルエルシー |
ヒト化抗cd19抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用
|
EP2468293B1
(en)
*
|
2006-09-28 |
2014-10-22 |
Merck Sharp & Dohme Corp. |
Use of pegylated il-10 to prevent metastasis of a cancer or tumor to the lung
|
WO2008043072A2
(en)
*
|
2006-10-05 |
2008-04-10 |
Biogen Idec Inc. |
Cd80 antagonists for treating neoplastic disorders
|
SG182183A1
(en)
|
2007-06-08 |
2012-07-30 |
Biogen Idec Inc |
Biomarkers for predicting anti-tnf responsiveness or non-responsiveness
|
KR101643514B1
(ko)
|
2007-07-09 |
2016-07-27 |
제넨테크, 인크. |
폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
|
RU2557319C2
(ru)
|
2007-07-16 |
2015-07-20 |
Дженентек, Инк. |
ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ
|
SG183023A1
(en)
|
2007-07-16 |
2012-08-30 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
EP2200631A1
(en)
|
2007-10-16 |
2010-06-30 |
Zymogenetics, Inc. |
Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
|
US7902147B2
(en)
|
2007-11-05 |
2011-03-08 |
Duke University |
Chronic lymphocytic leukemia prognosis and treatment
|
US7914785B2
(en)
|
2008-01-02 |
2011-03-29 |
Bergen Teknologieverforing As |
B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
EP2077281A1
(en)
|
2008-01-02 |
2009-07-08 |
Bergen Teknologioverforing AS |
Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
|
CN101981055B
(zh)
|
2008-01-31 |
2016-03-09 |
健泰科生物技术公司 |
抗cd79b抗体和免疫偶联物及使用方法
|
NZ603059A
(en)
|
2008-04-11 |
2014-07-25 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
治療進展型多發性硬化症之方法
|
US20100135900A1
(en)
*
|
2008-11-13 |
2010-06-03 |
Trubion Pharmaceuticals, Inc. |
Cd37 immunotherapeutic combination therapies and uses thereof
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
US20110142836A1
(en)
*
|
2009-01-02 |
2011-06-16 |
Olav Mella |
B-cell depleting agents for the treatment of chronic fatigue syndrome
|
DK2464725T3
(da)
|
2009-08-11 |
2020-06-02 |
Hoffmann La Roche |
Fremstilling af proteiner i glutaminfrie celledyrkningsmedier
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
WO2011100403A1
(en)
|
2010-02-10 |
2011-08-18 |
Immunogen, Inc |
Cd20 antibodies and uses thereof
|
US8822663B2
(en)
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
EP2625189B1
(en)
|
2010-10-01 |
2018-06-27 |
ModernaTX, Inc. |
Engineered nucleic acids and methods of use thereof
|
JP2014511687A
(ja)
|
2011-03-31 |
2014-05-19 |
モデルナ セラピューティクス インコーポレイテッド |
工学操作された核酸の送達および製剤
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
HUE057725T2
(hu)
|
2011-10-03 |
2022-06-28 |
Modernatx Inc |
Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása
|
HRP20220717T1
(hr)
|
2011-12-16 |
2022-07-22 |
Modernatx, Inc. |
Modificirani pripravci mrna
|
WO2013096346A1
(en)
*
|
2011-12-22 |
2013-06-27 |
Development Center For Biotechnology |
Bispecific t-cell activator antibody
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
AU2013243947A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
ES2921623T3
(es)
|
2012-11-26 |
2022-08-30 |
Modernatx Inc |
ARN modificado terminalmente
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
SG11201602261VA
(en)
|
2013-09-27 |
2016-04-28 |
Chugai Pharmaceutical Co Ltd |
Method for producing polypeptide heteromultimer
|
EP3052106A4
(en)
|
2013-09-30 |
2017-07-19 |
ModernaTX, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
EP3052521A1
(en)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
KR101723786B1
(ko)
|
2014-03-28 |
2017-04-06 |
가톨릭대학교 산학협력단 |
Il―21을 발현하는 중간엽 줄기세포를 포함하는 b 세포 림프종 예방 또는 치료용 조성물
|
WO2016049214A1
(en)
|
2014-09-23 |
2016-03-31 |
Genentech, Inc. |
METHOD OF USING ANTI-CD79b IMMUNOCONJUGATES
|
RU2730665C2
(ru)
*
|
2014-11-10 |
2020-08-24 |
Медиммун Лимитед |
Связывающие молекулы, специфичные в отношении CD73, и пути их применения
|
EA038349B1
(ru)
|
2014-11-21 |
2021-08-12 |
Бристол-Маерс Сквибб Компани |
Антитела, содержащие модифицированные константные участки тяжелой цепи
|
EA202090956A3
(ru)
|
2014-11-21 |
2020-12-30 |
Бристол-Майерс Сквибб Компани |
Антитела к cd73 и их применения
|
IL302486A
(en)
|
2015-06-24 |
2023-06-01 |
Hoffmann La Roche |
Antibodies against the transnephrine receptor with adapted affinity
|
MX2018002298A
(es)
|
2015-08-25 |
2018-07-06 |
Armo Biosciences Inc |
Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
|
SG10202002577XA
(en)
|
2015-09-21 |
2020-04-29 |
Aptevo Res & Development Llc |
Cd3 binding polypeptides
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
CA2997801A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
|
JP7219005B2
(ja)
|
2015-12-28 |
2023-02-07 |
中外製薬株式会社 |
Fc領域含有ポリペプチドの精製を効率化するための方法
|
EP3551034A1
(en)
|
2016-12-07 |
2019-10-16 |
Progenity, Inc. |
Gastrointestinal tract detection methods, devices and systems
|
WO2018151811A2
(en)
*
|
2017-02-17 |
2018-08-23 |
George Todaro |
Use of tgf alpha for the treatment of diseases and disorders
|
EP4108183A1
(en)
|
2017-03-30 |
2022-12-28 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
EP3606964A4
(en)
|
2017-04-03 |
2020-12-09 |
Immunomedics, Inc. |
SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY
|
US20230009902A1
(en)
|
2018-06-20 |
2023-01-12 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue orginating from the endoderm
|
US20230041197A1
(en)
|
2018-06-20 |
2023-02-09 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
CN113348011B
(zh)
|
2018-11-19 |
2023-04-18 |
比奥拉治疗股份有限公司 |
用生物治疗剂治疗疾病的方法和装置
|
CN115666704A
(zh)
|
2019-12-13 |
2023-01-31 |
比奥拉治疗股份有限公司 |
用于将治疗剂递送至胃肠道的可摄取装置
|